Drug Profile
Bedoradrine - Kissei Pharmaceutical/MediciNova
Alternative Names: Bedoradrine sulfate; KUR-1246; MLN-221; MN-221Latest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Kissei Pharmaceutical
- Developer Kissei Pharmaceutical; MediciNova
- Class Acetamides; Antiasthmatics; Ethanolamines; Naphthalenes; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute asthma
- Phase I Chronic obstructive pulmonary disease
- No development reported Preterm labour; Status asthmaticus
Most Recent Events
- 01 Mar 2022 MediciNova has patent protection for Bedoradrine for Acute asthma in USA
- 01 Mar 2022 MediciNova has patents pending for Bedoradrine in USA and other foreign countries
- 15 Apr 2021 Phase-I clinical trials in Chronic obstructive pulmonary disease in USA (IV) (MediciNova pipeline, April 2021)